Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William H Olson

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Clinical Therapeutics|August 6, 2016
Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient SettingSteven Deitelzweig, François Laliberté, Concetta Crivera, et al.
Hospital Practice (1995)|March 21, 2015
Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxabanGeno J Merli, Judd E Hollander, Patrick Lefebvre, et al.
Journal of Medical Economics|December 17, 2009
Development and validation of a new instrument to evaluate the ease of use of patient-controlled analgesic modalities for postoperative patientsGale Harding, Jeff R Schein, Winnie W Nelson, et al.
Advances in Therapy|April 21, 2015
Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin UsersFrançois Laliberté, Michel Cloutier, Concetta Crivera, et al.
Current Medical Research and Opinion|November 22, 2013
Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?François Laliberté, Dominic Pilon, Monika K Raut, et al.
Chest|June 11, 2004
Levofloxacin efficacy in the treatment of community-acquired legionellosisVictor L Yu, Richard N Greenberg, Neringa Zadeikis, et al.
Clinical Therapeutics|March 10, 2015
Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched usersFrançois Laliberté, Michel Cloutier, Concetta Crivera, et al.
Advances in Therapy|March 19, 2015
Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin usersFrançois Laliberté, Michel Cloutier, Concetta Crivera, et al.
Current Medical Research and Opinion|April 25, 2014
Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?François Laliberté, Dominic Pilon, Monika K Raut, et al.
Hospital Practice (1995)|September 26, 2014
Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapiesFrançois Laliberté, Dominic Pilon, Monika K Raut, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Clinical Therapeutics|August 6, 2016
Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient SettingSteven Deitelzweig, François Laliberté, Concetta Crivera, et al.
Hospital Practice (1995)|March 21, 2015
Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxabanGeno J Merli, Judd E Hollander, Patrick Lefebvre, et al.
Journal of Medical Economics|December 17, 2009
Development and validation of a new instrument to evaluate the ease of use of patient-controlled analgesic modalities for postoperative patientsGale Harding, Jeff R Schein, Winnie W Nelson, et al.
Advances in Therapy|April 21, 2015
Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin UsersFrançois Laliberté, Michel Cloutier, Concetta Crivera, et al.
Current Medical Research and Opinion|November 22, 2013
Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?François Laliberté, Dominic Pilon, Monika K Raut, et al.
Chest|June 11, 2004
Levofloxacin efficacy in the treatment of community-acquired legionellosisVictor L Yu, Richard N Greenberg, Neringa Zadeikis, et al.
Clinical Therapeutics|March 10, 2015
Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched usersFrançois Laliberté, Michel Cloutier, Concetta Crivera, et al.
Advances in Therapy|March 19, 2015
Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin usersFrançois Laliberté, Michel Cloutier, Concetta Crivera, et al.
Current Medical Research and Opinion|April 25, 2014
Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?François Laliberté, Dominic Pilon, Monika K Raut, et al.
Hospital Practice (1995)|September 26, 2014
Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapiesFrançois Laliberté, Dominic Pilon, Monika K Raut, et al.
Pageof 3